Effect of the COVID-19 pandemic on cancer treatment and research
Cet article discute des enjeux liés aux traitements anticancéreux dispensés aux patients atteints d’un cancer pendant la crise sanitaire liée à la pandémie du COVID-19
The coronavirus disease 2019 (COVID-19) outbreak, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has rapidly escalated into a global pandemic. Patients with haematological and other cancers,1, 2 and recipients of haematopoietic stem cell transplantation (HSCT), could be at particular risk from COVID-19, since they tend to be older, have multiple comorbidities, and are often immunosuppressed by their disease or therapy. A retrospective analysis of 355 patients who died of COVID-19 in Italy showed that 20% had active cancer,3 and a study from 2013–17 of 678 patients who had an HSCT found that 112 (17%) developed human coronavirus infection, of whom 34 had lower respiratory tract infection.4 However, evidence regarding the effect of COVID-19 on patients with cancer is inadequate. (...)